logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Cost-Utility Analysis of Acetylcholinesterase inhibitors in the Treatment of Mild to Moderate Alzheimer’s disease (in Thai language)

Home > Research Projects > Strategy 3 : HTA Research > Cost-Utility Analysis of Acetylcholinesterase inhibitors in the Treatment of Mild to Moderate Alzheimer’s disease (in Thai language)

Project Code

01-305-2550

Research team

Researchers

Saowalak Turongkaravee, M.Sc

Co - Researcher

-

Project Details

Strategies
Category
Support
Tags
Project duration

Start: 8 October 2007
End: 8 October 2014

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 1608

Publish date23 November 2011 22:40

Project Summary

The objective of this study is to estimate the cost-utility analysis of the cholinesterase inhibitors (i.e., donepezil, galantamine and rivastigmine) compared with no drug treatment in patients with mild to moderate alzheimer’s disease (AD) in Thailand based on the societal and governmental perspectives and to estimate the budget impact of the cholinesterase inhibitors when including these drugs on the national list of essential drugs (NLED) for precribing to mild to moderate AD patients. In addition, this study also investigates the experiences and perspectives of family caregivers and medical doctors in order to understand the overall context of AD in Thailand. The results can be used as a guideline or as data for health policy makers to determine which treatment should be included in the NLED to be given to mild to moderate AD patients.  

Documents

Activity

Health Intervention and Technology Assessment Program Foundation
Head Office : 88/22 Moo 4, 6th Building, 6th Floor, Department of Health, Ministry of Public Health, Tiwanon Road, Taladkwan Subdistrict, Muang Nonthaburi District, Nonthaburi 11000, Thailand


Tel. : +662-590-4549, +662-590-4374-5
Fax : +662-590-4369
E-mail : [email protected]
Website : www.hitap.net


© Copyright - HITAP 2014
Top